论文部分内容阅读
临床上门脉高压主要并发症之一为食管胃底静脉曲张破裂出血(EGV),死亡率较高。这些患者在急性出血时常伴有失血性休克,部分有腹水、黄疸和严重的凝血机制障碍,使外科手术受到限制。故在急性出血期,内科治疗显得十分重要。而止血效果的好坏,与临床用药选择直接相关。我科于1994年6月～2000年6月,收治肝硬化门脉高压食管胃底静脉曲张破裂出血病人共117例,其中单用垂体后叶素治疗EGV病人38例(A组),垂体后叶素联用酚妥拉明治疗EGV病人39例(B组),单用奥曲肽治疗EGV病人40例(C组)。现将3组临床上的止血效果、副反应,予以对照分析。
Clinically, one of the major complications of portal hypertension is esophageal and gastric variceal bleeding (EGV), with a high mortality rate. These patients are often accompanied by hemorrhagic shock in acute hemorrhage, some with ascites, jaundice and severe clotting mechanism obstacles that make surgery limited. Therefore, in acute bleeding, medical treatment is very important. The hemostatic effect is good or bad, and is directly related to the choice of clinical medication. Our department in June 1994 ~ June 2000, admitted to cirrhosis and portal hypertension in patients with esophageal varices bleeding in 117 cases, of which only pituitrin treatment of EGV in 38 patients (group A), after pituitary Forty-three patients with EGV treated with vetiver and phentolamine (group B), and 40 patients treated with octreotide alone (group C). Now 3 sets of clinical hemostatic effects, side effects, to be controlled analysis.